-
2023
-
FDA Approves Evkeeza for Kids With Ultra-Rare Cholesterol Disorder
-
EU Authorizes Dupixent for Young Kids With Severe Atopic Dermatitis
-
FDA Approves Rezzayo, a Novel Echinocandin
-
FDA Approves Sandoz’s Citrate-Free Adalimubab Formulation
-
AstraZeneca and Ionis build case for amyloidosis drug eplontersen
-
FDA Approves First-Ever Treatment for Activated Phosphoinositide 3-Kinase Delta Syndrome
-
NICE Recommends Upstaza for Rare Genetic Disorder
-
Incyte Gets CRL for Jakafi Extended-Release Tablets
-
Glenmark Pharmaceuticals’ Generic of Leo Pharma’s Enstilar Approved
-
Cyclerion’s Mitochondrial Diseases Candidate Gets Orphan Drug Nod